(KROS) Keros Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KROS) Keros Therapeutics, Inc. Complete Analysis Pack
See the Bigger Picture
This Keros Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
KER-050 flagship protein therapeutic
KER-050 is Keros Therapeutics, Inc.’s lead and most advanced program, so it drives most of the pipeline’s long-term value. As of end-2025, it was still in clinical development and had not reached commercial launch, so it was not yet a true BCG Star. In BCG terms, it is better viewed as a high-potential Question Mark with a real shot at becoming a Star if late-stage data and approval follow.
MDS cytopenias target
KER-050 targets MDS cytopenias, with anemia and thrombocytopenia at the core of a high-unmet-need hematology niche. Myelodysplastic syndromes affect about 10,000 to 15,000 new U.S. patients a year, but broad commercial scale was still ahead because the asset remained in development. That makes it a classic Star for Keros Therapeutics, Inc.: strong upside, but still pre-revenue.
Myelofibrosis program
KER-050 targets myelofibrosis, a rare bone marrow cancer with about 1.5 new cases per 100,000 people each year and a median survival near 5 to 7 years. The need is still high because current options do not work well for many patients. At end-2025, this stayed a development-stage asset, so it was not a market-leading Star.
Protein therapeutic platform
KER-050 is an investigational protein therapeutic, so it is not yet a marketed product, but it sits at the center of Keros Therapeutics, Inc.’s pipeline and could become a "Star" if late-stage data and FDA approval land. The label fits the BCG "Star" logic only if it scales into revenue; today, the asset is still a clinical-stage bet, not a cash generator.
- KER-050 is the lead pipeline asset.
- No product sales yet.
- Future Star depends on Phase data.
- Approval would unlock commercial value.
Highest priority pipeline asset
KER-050 is Keros Therapeutics, Inc.’s most advanced asset and the clearest near-term driver of value. As of end-2025, Keros had no approved commercial product, so KER-050 still fit as a potential Star, not an established one. Its lead status matters because it carries the highest read-through for future revenue and valuation.
- Most advanced Keros program
- Best near-term value catalyst
- No approved product at end-2025
Keros Lacks a BCG Star, But KER-050 Keeps Hope Alive
Keros Therapeutics, Inc. had no true BCG Star at end-2025 because it had no approved, revenue-generating product. KER-050 was the closest asset, with 2025 year-end cash of about $277.8 million supporting development, but it still sat in clinical stage, so it is better treated as a future Star candidate than an actual Star.
| Metric | 2025 |
|---|---|
| Approved products | 0 |
| Year-end cash | $277.8M |
| Lead asset | KER-050 |
| BCG Star status | No |
What is included in the product
Detailed Word Document
Keros Therapeutics’ BCG Matrix likely centers on pipeline assets as Question Marks, with no clear Cash Cows yet.
Editable Excel File
Clean BCG snapshot for Keros Therapeutics, Inc. that simplifies portfolio decisions and highlights growth priorities.
Reference Sources
Provides a credible source trail for Keros Therapeutics, helping investors verify key claims and make faster, better-informed decisions.
Cash Cows
No approved products
Keros Therapeutics, Inc. had no approved or marketed products at end-2025, so it had no true cash cow in the BCG sense. Its portfolio remained clinical-stage only, which means no mature asset was generating steady product sales or cash flow. In this setup, cash generation depended on financing and pipeline progress, not on a legacy product.
No commercial franchise
Keros Therapeutics had no commercial franchise, so it had no cash cow in the BCG sense. The Company reported $0 product revenue in 2025, showing it still had no branded therapy to sell in a mature market. Instead of milking steady cash flow, it stayed a development-stage biotech that relied on capital markets to fund R&D.
No recurring product sales
Keros Therapeutics, Inc. had no recurring product sales because its pipeline was still clinical-stage, with no approved, sales-stage assets. That left it without a steady cash engine from product revenue in the latest fiscal period. In other words, its value sat in development programs, not repeat commercial sales.
No low-growth leader
Keros Therapeutics had no cash-cow business because it had not launched any approved product, so its product revenue was $0. Cash cows are mature, low-growth assets with steady sales, but Keros was still in the R&D stage, with its pipeline seeking proof of efficacy, safety, and FDA approval.
- No commercial products: $0 revenue
- No dominant mature asset
- Pipeline still in clinical testing
- Value depends on approval, not harvest
No cash-cow unit
Keros Therapeutics had no classic cash cow at end-2025. KER-050, KER-047, and KER-012 were still in clinical trials, so none generated stable, mature cash flow. The company also reported no product revenue in 2025, so the BCG matrix shows no cash-cow unit.
- No approved, cash-generating unit
- All key programs were still clinical
- End-2025 cash cow: none
Keros Had No Cash Cow in 2025: Zero Revenue, No Approved Products
Keros Therapeutics had no cash cow at end-2025 because it had no approved products and reported $0 product revenue. All core programs, including KER-050, KER-047, and KER-012, were still in clinical development, so the Company had no mature asset generating steady cash flow.
| Metric | 2025 |
|---|---|
| Product revenue | $0 |
| Approved products | 0 |
| Commercial cash cow | None |
| Lead programs | Clinical-stage only |
Preview the Actual Deliverable
Keros Therapeutics, Inc. Reference Sources
You're previewing the exact Keros Therapeutics, Inc. BCG Matrix document you'll receive after purchase. No sample pages, no demo content—just the full, final report. It’s ready for immediate use in analysis, presentations, or strategic planning.
Dogs
No legacy commercial brand
Keros Therapeutics, Inc. had no legacy commercial brand in its 2025 reporting, and it did not show any old marketed drug with weak growth. The Company was still clinical-stage, so its asset base was focused on pipeline programs, not sales. That leaves no clear "dog" asset to identify in the BCG Matrix.
No low-share mature product
Keros Therapeutics, Inc. had 0 approved products and no measurable market share in FY2025, so it had no classic "Dog" in the BCG sense. "Dogs" are low-share, low-growth assets, but Keros’s pipeline was still pre-commercial, led by elritercept and other clinical-stage programs. So the matrix snapshot points to absence, not decline.
No divestiture candidate named
No divestiture candidate was named for Keros Therapeutics, Inc., and the supplied material showed only active development programs. So the Dogs bucket is effectively 0 identified assets, not a failed product line. With no discontinued product singled out, there was no clear divestiture case.
No cash trap product
Keros Therapeutics, Inc. was still pre-commercial in 2025, so it had no legacy product line burning cash like a classic Dog. Its spending stayed R and D-led, with no mature-market maintenance load or product support costs to trap capital.
That matters because Dogs usually tie up cash in low-growth assets, but Keros had 0 product revenue and was still funding pipeline work instead of defending old sales. In its latest filings, the company’s cash use was driven by research, not a cash-draining franchise.
- No legacy product cash trap
- Pre-commercial in 2025
- 0 product revenue
- R and D was the main spend
No failed marketed unit
Keros Therapeutics, Inc. had no marketed unit at end-2025, so there was no mature product with weak growth to place in the Dog quadrant. The Company remained a pure R&D story, with 2025 revenue still zero and no commercial franchise to fade. Its pipeline was still clinical-stage, so no failed marketed asset stood out.
- No marketed product in 2025
- Revenue stayed at $0
- No mature decline case
- Dog quadrant not applicable
Keros Therapeutics Had No Dog Asset in FY2025
Keros Therapeutics, Inc. had no Dog asset in FY2025. It was still clinical-stage, with $0 product revenue and no marketed product to place in a low-share, low-growth bucket. So the Dog quadrant was not applicable.
| FY2025 metric | Value |
|---|---|
| Product revenue | $0 |
| Approved products | 0 |
| Marketed Dog asset | None |
Question Marks
KER-047 Phase 1
KER-047 was a small-molecule anemia candidate in Phase 1, so it sat in Keros Therapeutics, Inc.’s Question Mark bucket: early data, high technical risk, and big upside if it showed meaningful hemoglobin gains. In BCG terms, Phase 1 means the asset was still pre-proof, with success odds far below later-stage programs and no revenue yet.
KER-012 Phase 1
KER-012 is Keros Therapeutics, Inc.'s Phase 1 asset, and it is being tested in 3 areas: osteoporosis, osteogenesis imperfecta, and pulmonary arterial hypertension. That early stage, plus the wide spread of possible uses, makes it a textbook Question Mark: high upside if data improve, but no clear commercial proof yet.
Anemia pipeline
Keros Therapeutics’ anemia pipeline fits the Question Mark box: it targets a medically important, still underserved market, but end-2025 share was effectively 0% because the programs were still clinical-stage. The core assets, including elritercept, were aimed at severe anemia in myelodysplastic syndromes and beta-thalassemia, where transfusion dependence remains common. In 2025, the addressable market was large, but revenue was still minimal.
Musculoskeletal pipeline
Keros Therapeutics, Inc.'s musculoskeletal pipeline is a Question Mark in the BCG Matrix. KER-012 targets osteoporosis and osteogenesis imperfecta, two high-need markets, but it had not yet been proven in humans, so the program still carried high clinical risk.
This makes the asset a possible upside driver, but not a sure one.
- KER-012 targets two rare bone diseases.
- Human proof of concept is still missing.
- High need, but high trial risk.
All clinical-stage programs
Keros Therapeutics, Inc.’s clinical-stage pipeline is mostly Question Marks under BCG logic because it has active development assets, not revenue-generating brands. KER-050, KER-047, and KER-012 all still need more clinical data, so their path to Star status depends on proof of efficacy, safety, and clear market demand.
- All three programs are pre-commercial.
- More data is needed for Star status.
- Portfolio value is still tied to trial results.
Keros’ High-Risk Clinical Bets: Big Upside, Little Proof
Keros Therapeutics, Inc.’s Question Marks are KER-047, KER-012, and KER-050: all clinical-stage, all pre-revenue, and all still waiting on proof. Their upside is tied to large unmet-need areas like anemia, osteoporosis, OI, and PAH, but Phase 1 data keep technical risk high.
| Asset | Stage | BCG read |
|---|---|---|
| KER-047 | Phase 1 | High risk, high upside |
| KER-012 | Phase 1 | Early proof needed |
| KER-050 | Clinical | Still unproven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.